Abstract
Purpose
The purpose of this study is to assess the feasibility of targeted treatment for pulmonary mucoepidermoid carcinoma (PMEC) by investigating track record of the epidermal growth factor receptor (EGFR) mutation status in PMEC.
Methods
From January 2001 to December 2009, 20 PMEC patients (11 males and 9 females) received treatment in our center. All the patients received surgery and were diagnosed by pathology. Sequencing analysis was used to monitor exons 18–21 of the EGFR gene mutation.
Results
The exon 21 L861Q heterozygous mutation was confirmed in five patients. There was no case with any deletion in exon 19 or exon 21 L858R mutation. One case was with a homonymy exon 18 mutation (I760I). Exon 20 G2607A (Q787Q) SNP was found in 12 of those 20 patients.
Conclusion
L861Q mutation in exon 21 is the most frequent feature of heterozygous mutation in our study. Further investigations will be required to validate our findings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chin CH, Huang CC, Lin MC, Chao TY, Liu SF (2008) Prognostic factors of tracheobronchial mucoepidermoid carcinoma-15 years experience. Respirology 13:275–280
Dahse R, Driemel O, Schwarz S, Dahse J, Kromeyer-Hauschild K, Berndt A, Kosmehl H (2009) Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br J Cancer 100:623–625
Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW et al (2008) Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer 61:30–34
Heitmiller RF, Mathisen DJ, Ferry JA, Mark EJ, Grillo HC (1989) Mucoepidermoid lung tumors. Ann Thorac Surg 47:394–399
Kang DY, Yoon YS, Kim HK, Choi YS, Kim K, Shim YM, Kim J (2011) Primary salivary gland-type lung cancer: surgical outcomes. Lung Cancer 72:250–254
Leonardi HK, Jung-Legg Y, Legg MA, Neptune WB (1978) Tracheobronchial mucoepidermoid carcinoma. Clinicopathological features and results of treatment. J Thorac Cardiovasc Surg 76:431–438
Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE et al (2008) Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21:1168–1175
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
Miller DL, Allen MS (1993) Rare pulmonary neoplasms. Mayo Clin Proc 68:492–498
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M et al (2006) MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res 12:3902–3907
O’Neill ID (2009) Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung:possible significance of CRTC1-MAML2 oncogene. Lung Cancer 64:129–130
Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774
Rossi G, Sartori G, Cavazza A, Tamberi S (2009) Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis. Lung Cancer 63:159–160
Smetana HF, Iverson L, Swan LL (1952) Bronchogenic carcinoma; analysis of 100 autopsy cases. Mil Surg 111:335–351
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537
Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, EI-Naggar AK (2007) CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin’s tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer 46:708–715
Vadasz P, Egervary M (2000) Mucoepidermoid bronchial tumors: a review of 34 operated cases. Eur J Cardiothorac Surg 17:566–569
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC (2011) Effectiveness of tyrosine kinase inhibitors on ‘‘uncommon’’ epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 17:3812–3821
Yamamoto H, Toyooka S, Mitsudomi T (2009) Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 63:315–321
Conflict of interest
The authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Reported in part in the 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3–7, 2011.
Yongfeng Yu and Zhengbo Song have equally contributed to this work.
Rights and permissions
About this article
Cite this article
Yu, Y., Song, Z., Gao, H. et al. EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma. J Cancer Res Clin Oncol 138, 1421–1425 (2012). https://doi.org/10.1007/s00432-012-1211-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1211-5